Clinical Benefit of Delamanid (OPC-67683) in the Treatment of Multidrug-Resistant Tuberculosis Patients in China
Authors:
- 2 April 2013
- journal article
- research article
- Published by Springer Nature in Cell Biochemistry and Biophysics
- Vol. 67 (3) , 957-963
Abstract
The cure rates are much lower for multidrug-resistant (MDR) tuberculosis (TB) patients. Delamanid (OPC-67683) has been evaluated in phase-II MDR-TB clinical trials. Herein, we reviewed MDR-TB cases in which treatment regimens, with/without delamanid, were administered. Thirty-eight patients were enrolled; 26 received delamanid-containing regimens (treatment group) while 12 received placebo-containing regimens (control group) for 56 days. Data regarding clinical/radio-microbiological characteristics, drug tolerability, and treatment outcomes were collected. We found that all patients had isolates resistant to a median of 5 (range 2–7) drugs; 24 (92.3 %) patients in treatment group and 11 (91.7 %) in control group had cavities. Culture conversion was obtained in 32 pulmonary TB cases (median 74.5 days). At data censure, 30/38 patients successfully completed therapy with documented negative cultures for at least 18 months before the end of treatment. Two patients (5 consecutive negative cultures) are still on treatment. Six patients had poor outcome (3 failures/2 lost/1 death). In 13 patients, adverse events were observed that included mental disorder, QT interval prolongation, and increased blood cortisol whereas only 3 patients stopped delamanid treatment because of adverse events. It was, therefore, concluded that delamanid was well-tolerated, had low rates of discontinuation, and could be effective for treating MDR-TB.Keywords
This publication has 13 references indexed in Scilit:
- A Reader's Guide to 200 Years of the New England Journal of MedicineNew England Journal of Medicine, 2012
- Linezolid in the Treatment of Multidrug‐Resistant TuberculosisClinical Infectious Diseases, 2010
- Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-AnalysisPLOS ONE, 2009
- Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance SurveillanceThe Lancet, 2009
- Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisThe Lancet Infectious Diseases, 2009
- Multidrug-resistant and extensively drug-resistant tuberculosis: a reviewCurrent Opinion in Infectious Diseases, 2008
- Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Treatment Outcomes for HIV‐Uninfected Patients with Multidrug‐Resistant and Extensively Drug‐Resistant TuberculosisClinical Infectious Diseases, 2008
- Randomized Trials to Optimize Treatment of Multidrug-Resistant TuberculosisPLOS Medicine, 2007
- Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, PeruNew England Journal of Medicine, 2003